Question mark
Once a full word has been entered your search results will begin to display, for example if you were searching for spectrum analysers, the search will predict results once spectrum is entered

DIAGNOSTIC BIOMARKERS

Local Distributor Manufacturer Model Number (if applicable) Specifications
BIO-STRATEGY LIMITED BIO-STRATEGY LIMITED NANOSTRING TECHNOLOGIES
nCounter Profiler - SPRINT nCounter Analysis System - Max nCounter Analysis System Flex Fully Automated System for Translational Research Enables direct digital counting of individual RNA and DNA molecules in a sample. Superior quantitative precision than qPCR without RT or PCR steps. Sensitive, single tube multiplexing of over 800 genes or regions. Complete system, includes Prep Station + Digital Analyser. Flexible sample requirements - small samples from a variety of sources, including FFPE. Quality assurance - GMP compliant, ISO 13485 certified.
Prosigna™ Breast Cancer Prognostic Gene Signature Assay The Prosigna™ Breast Cancer Prognostic Gene Signature Assay is an in vitro diagnostic assay which uses the gene expression profile of cells found in breast cancer tissue to assess a patient’s risk of distant recurrence. The assay measures the gene expression profile using RNA extracted from Formalin-Fixed, Paraffin-Embedded (FFPE) breast tumor tissue. The gene expression data are weighted together with clinical variables to generate both a subtype (luminal A, luminal B, HER2-enriched, or basal-like) and a score indicative of the probability of distant recurrence of disease. The assay is performed on the NanoString nCounter® Analysis System using FFPE breast tumor tissue previously diagnosed as invasive breast carcinoma.
BIO-STRATEGY LIMITED BIO-STRATEGY LIMITED QIAGEN
QIAseq, DNAseq, PCR Array, qBiomarker QIAGEN provides a broad range of assay technologies for biomarker discovery and verification. These assay technologies detect or measure gene expression, epigenetic modifications, and genotype. Biomarkers and their assays have to be reliable, measurable, specific, and predictive. The spectrum of biomarkers suggests that no single technology or discipline can cover the whole biomarker discovery field. Collaborative efforts are required in the fields of genomics, epigenomics, proteomics, metabolomics, epidemiology, and methodologies such as imaging, cytometry, and histology.